{"id":"glyceryl-trinitrate","rwe":[],"_fda":{"id":"2ac009f2-257f-4603-a1e8-c50aa9e31f4b","risks":["Risk Summary Limited published data on the use of nitroglycerin are insufficient to determine a drug associated risk of major birth defects or miscarriage. In animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose [see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Risk Summary Sublingual nitroglycerin has not been studied in lactating women. It is not known if nitroglycerin is present in human milk or if nitroglycerin has effects on milk production."],"set_id":"041f127e-5166-4484-bc1a-0a373d1187ae","openfda":{"nui":["N0000175415","M0014874","N0000009909"],"unii":["G59M7S0WS3"],"route":["SUBLINGUAL"],"rxcui":["198038","198039","198040"],"spl_id":["2ac009f2-257f-4603-a1e8-c50aa9e31f4b"],"brand_name":["NITROGLYCERIN"],"spl_set_id":["041f127e-5166-4484-bc1a-0a373d1187ae"],"package_ndc":["59762-4921-1","59762-3304-1","59762-3304-3","59762-0489-1"],"product_ndc":["59762-0489","59762-4921","59762-3304"],"generic_name":["NITROGLYCERIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Nitrates [CS]"],"pharm_class_pe":["Vasodilation [PE]"],"substance_name":["NITROGLYCERIN"],"pharm_class_epc":["Nitrate Vasodilator [EPC]"],"manufacturer_name":["Mylan Pharmaceuticals Inc."],"application_number":["NDA021134"],"is_original_packager":[true]},"version":"15","pregnancy":["8.1 Pregnancy Risk Summary Limited published data on the use of nitroglycerin are insufficient to determine a drug associated risk of major birth defects or miscarriage. In animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose [see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data No embryotoxic or postnatal development effects were observed with transdermal application in pregnant rabbits and rats at doses up to 80 and 240 mg/kg/day, respectively, at intraperitoneal doses in pregnant rats up to 20 mg/kg/day from gestation day 7-17, and at intravenous doses in pregnant rabbits up to 4 mg/kg/day from gestation day 6-18."],"overdosage":["10 OVERDOSAGE 10.1 Signs and Symptoms, Methemoglobinemia Nitrate overdosage may result in: severe hypotension, persistent throbbing headache, vertigo, palpitation, visual disturbance, flushing and perspiring skin (later becoming cold and cyanotic), nausea and vomiting (possibly with colic and even bloody diarrhea), syncope (especially in the upright posture), methemoglobinemia with cyanosis and anorexia, initial hyperpnea, dyspnea and slow breathing, slow pulse (dicrotic and intermittent), heart block, increased intracranial pressure with cerebral symptoms of confusion and moderate fever, paralysis and coma followed by clonic convulsions, and possibly death due to circulatory collapse. Case reports of clinically significant methemoglobinemia are rare at conventional doses of organic nitrates. The formation of methemoglobin is dose-related and in the case of genetic abnormalities of hemoglobin that favor methemoglobin formation, even conventional doses of organic nitrates could produce harmful concentrations of methemoglobin. 10.2 Treatment of Overdosage As hypotension associated with nitroglycerin overdose is the result of venodilatation and arterial hypovolemia, prudent therapy in this situation should be directed toward increase in central fluid volume. No specific antagonist to the vasodilator effects of nitroglycerin is known. Keep the patient recumbent in a shock position and comfortably warm. Passive movement of the extremities may aid venous return. Intravenous infusion of normal saline or similar fluid may also be necessary. Administer oxygen and artificial ventilation, if necessary. If methemoglobinemia is present, administration of methylene blue (1% solution), 1-2 mg per kilogram of body weight intravenously, may be required unless the patient is known to have G-6-PD deficiency. If an excessive quantity of nitroglycerin has been recently swallowed gastric lavage may be of use. As epinephrine is ineffective in reversing the severe hypotensive events associated with overdosage, it is not recommended for resuscitation."],"description":["11 DESCRIPTION Nitroglycerin sublingual tablets are stabilized sublingual compressed tablets that contain 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as lactose monohydrate, NF; glyceryl monostearate, NF; pregelatinized starch, NF; calcium stearate, NF powder; and silicon dioxide, colloidal, NF. Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the chemical structure is: Molecular weight: 227.09 Nitroglycerin Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Nitroglycerin Sublingual Tablets are supplied as white, round, flat-faced tablets in 3 strengths (0.3 mg, 0.4 mg, and 0.6 mg) in bottles containing 100 tablets each, with color-coded labels, and in color-coded Patient Convenience Packages of 4 bottles of 25 tablets each. 0.3 mg: Coded “N” on one side and “3” on the other. NDC 59762-4921-1—Bottle of 100 tablets 0.4 mg: Coded “N” on one side and “4” on the other. NDC 59762-3304-2—Bottle of 25 tablets NDC 59762-3304-3—Convenience Package Carton of 4 Bottles of 25 tablets NDC 59762-3304-1—Bottle of 100 tablets 0.6 mg: Coded “N” on one side and “6” on the other. NDC 59762-0489-1—Bottle of 100 tablets Store at Controlled Room Temperature 20°–25°C (68°–77°F) [see USP]. Nitroglycerin should be kept in the original glass container and must be tightly capped after each use to prevent loss of tablet potency."],"geriatric_use":["8.5 Geriatric Use Clinical studies of nitroglycerin sublingual tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of nitroglycerin in pediatric patients have not been established."],"effective_time":"20241015","pharmacodynamics":["12.2 Pharmacodynamics The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload). Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral vascular resistance and arterial pressure (afterload), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear. Therapeutic doses of nitroglycerin may reduce systolic, diastolic, and mean arterial blood pressure. Effective coronary perfusion pressure is usually maintained, but can be compromised if blood pressure falls excessively, or increased heart rate decreases diastolic filling time. Elevated central venous and pulmonary capillary wedge pressures, and pulmonary and systemic vascular resistance are also reduced by nitroglycerin therapy. Heart rate is usually slightly increased, presumably due to a compensatory response to the fall in blood pressure. Cardiac index may be increased, decreased, or unchanged. Myocardial oxygen consumption or demand (as measured by the pressure-rate product, tension-time index, and stroke-work index) is decreased and a more favorable supply-demand ratio can be achieved. Patients with elevated left ventricular filling pressures and increased systemic vascular resistance in association with a depressed cardiac index are likely to experience an improvement in cardiac index. In contrast, when filling pressures and cardiac index are normal, cardiac index may be slightly reduced following nitroglycerin administration. Consistent with the symptomatic relief of angina, digital plethysmography indicates that onset of the vasodilatory effect occurs approximately 1 to 3 minutes after sublingual nitroglycerin administration and reaches a maximum by 5 minutes postdose. Effects persist for at least 25 minutes following nitroglycerin sublingual tablets administration."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Nitroglycerin is rapidly absorbed following sublingual administration of nitroglycerin sublingual tablets. Mean peak nitroglycerin plasma concentrations occur at a mean time of approximately 6 to 7 minutes postdose (Table 1). Maximum plasma nitroglycerin concentrations (C max ) and area under the plasma concentration-time curves (AUC) increase dose-proportionally following 0.3 to 0.6 mg nitroglycerin sublingual tablets. The absolute bioavailability of nitroglycerin from nitroglycerin sublingual tablets is approximately 40% but tends to be variable due to factors influencing drug absorption, such as sublingual hydration and mucosal metabolism. Table 1 Parameter Mean Nitroglycerin (SD) Values 2 × 0.3 mg Nitroglycerin Sublingual Tablets 1 × 0.6 mg Nitroglycerin Sublingual Tablets C max , ng/mL 2.3 (1.7) 2.1 (1.5) T max , min 6.4 (2.5) 7.2 (3.2) AUC(0–∞), min 14.9 (8.2) 14.9 (11.4) t½, min 2.8 (1.1) 2.6 (0.6) Distribution The volume of distribution (V Area ) of nitroglycerin following intravenous administration is 3.3 L/kg. At plasma concentrations between 50 and 500 ng/mL, the binding of nitroglycerin to plasma proteins is approximately 60%, while that of 1,2- and 1,3-dinitroglycerin is 60% and 30%, respectively. Metabolism A liver reductase enzyme is of primary importance in the metabolism of nitroglycerin to glycerol di- and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, 2 major metabolites 1,2- and 1,3‑dinitroglycerin, are found in plasma. Mean peak 1,2- and 1,3-dinitroglycerin plasma concentrations occur at approximately 15 minutes postdose. The elimination half-life of 1,2- and 1,3-dinitroglycerin is 36 and 32 minutes, respectively. The 1,2- and 1,3‑dinitroglycerin metabolites have been reported to possess approximately 2% and 10%, respectively, of the pharmacological activity of nitroglycerin. Higher plasma concentrations of the dinitro metabolites, along with their nearly 10-fold longer elimination half-lives, may contribute significantly to the duration of pharmacologic effect. Glycerol mononitrate metabolites of nitroglycerin are biologically inactive. Elimination Nitroglycerin plasma concentrations decrease rapidly, with a mean elimination half-life of 2 to 3 minutes. Half-life values range from 1.5 to 7.5 minutes. Clearance (13.6 L/min) greatly exceeds hepatic blood flow. Metabolism is the primary route of drug elimination. Drug interactions Aspirin: Coadministration of nitroglycerin with high dose aspirin (1000 mg) results in increased exposure to nitroglycerin. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of nitroglycerin with high dose aspirin. Tissue-type plasminogen activator (t-PA) : Concomitant administration of t-PA and intravenous nitroglycerin has been shown to reduce plasma levels of t-PA and its thrombolytic effect."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail elsewhere in the label: • Hypotension [see Warnings and Precautions (5.2) ] • Headache [see Warnings and Precautions (5.4) ] • Hypersensitivity [see Contraindications (4.4) ] Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally, particularly in erect, immobile patients. Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea, vomiting, weakness, diaphoresis, pallor, and collapse) may occur at therapeutic doses. Syncope due to nitrate vasodilatation has been reported. Flushing, drug rash, and exfoliative dermatitis have been reported in patients receiving nitrate therapy. Most common adverse reactions occurring at a frequency greater than 2% are headache, dizziness and paresthesia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS • Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. ( 4.1 , 7.1 ) • Severe anemia ( 4.2 ) • Increased intracranial pressure ( 4.3 ) • Hypersensitivity to nitroglycerin or to other nitrates or nitrites or any excipient ( 4.4 ) • Circulatory failure and shock ( 4.5 ) 4.1 PDE-5-Inhibitors and sGC-Stimulators Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions (7.1) ]. Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. 4.2 Severe Anemia Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). 4.3 Increased Intracranial Pressure Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). 4.4 Hypersensitivity Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. 4.5 Circulatory Failure and Shock Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."],"drug_interactions":["7 DRUG INTERACTIONS Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use. ( 7.2 ) 7.1 PDE-5-Inhibitors and sGC-Stimulators Nitroglycerin sublingual tablets are contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. Nitroglycerin sublingual tablets are contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators. Concomitant use can cause hypotension. The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended. Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion. 7.2 Ergotamine Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability. Ergotamine is known to precipitate angina pectoris. Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible.","Drug interactions Aspirin: Coadministration of nitroglycerin with high dose aspirin (1000 mg) results in increased exposure to nitroglycerin. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of nitroglycerin with high dose aspirin. Tissue-type plasminogen activator (t-PA) : Concomitant administration of t-PA and intravenous nitroglycerin has been shown to reduce plasma levels of t-PA and its thrombolytic effect."],"mechanism_of_action":["12.1 Mechanism of Action Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation. 12.2 Pharmacodynamics The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload). Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral vascular resistance and arterial pressure (afterload), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear. Therapeutic doses of nitroglycerin may reduce systolic, diastolic, and mean arterial blood pressure. Effective coronary perfusion pressure is usually maintained, but can be compromised if blood pressure falls excessively, or increased heart rate decreases diastolic filling time. Elevated central venous and pulmonary capillary wedge pressures, and pulmonary and systemic vascular resistance are also reduced by nitroglycerin therapy. Heart rate is usually slightly increased, presumably due to a compensatory response to the fall in blood pressure. Cardiac index may be increased, decreased, or unchanged. Myocardial oxygen consumption or demand (as measured by the pressure-rate product, tension-time index, and stroke-work index) is decreased and a more favorable supply-demand ratio can be achieved. Patients with elevated left ventricular filling pressures and increased systemic vascular resistance in association with a depressed cardiac index are likely to experience an improvement in cardiac index. In contrast, when filling pressures and cardiac index are normal, cardiac index may be slightly reduced following nitroglycerin administration. Consistent with the symptomatic relief of angina, digital plethysmography indicates that onset of the vasodilatory effect occurs approximately 1 to 3 minutes after sublingual nitroglycerin administration and reaches a maximum by 5 minutes postdose. Effects persist for at least 25 minutes following nitroglycerin sublingual tablets administration. 12.3 Pharmacokinetics Absorption Nitroglycerin is rapidly absorbed following sublingual administration of nitroglycerin sublingual tablets. Mean peak nitroglycerin plasma concentrations occur at a mean time of approximately 6 to 7 minutes postdose (Table 1). Maximum plasma nitroglycerin concentrations (C max ) and area under the plasma concentration-time curves (AUC) increase dose-proportionally following 0.3 to 0.6 mg nitroglycerin sublingual tablets. The absolute bioavailability of nitroglycerin from nitroglycerin sublingual tablets is approximately 40% but tends to be variable due to factors influencing drug absorption, such as sublingual hydration and mucosal metabolism. Table 1 Parameter Mean Nitroglycerin (SD) Values 2 × 0.3 mg Nitroglycerin Sublingual Tablets 1 × 0.6 mg Nitroglycerin Sublingual Tablets C max , ng/mL 2.3 (1.7) 2.1 (1.5) T max , min 6.4 (2.5) 7.2 (3.2) AUC(0–∞), min 14.9 (8.2) 14.9 (11.4) t½, min 2.8 (1.1) 2.6 (0.6) Distribution The volume of distribution (V Area ) of nitroglycerin following intravenous administration is 3.3 L/kg. At plasma concentrations between 50 and 500 ng/mL, the binding of nitroglycerin to plasma proteins is approximately 60%, while that of 1,2- and 1,3-dinitroglycerin is 60% and 30%, respectively. Metabolism A liver reductase enzyme is of primary importance in the metabolism of nitroglycerin to glycerol di- and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, 2 major metabolites 1,2- and 1,3‑dinitroglycerin, are found in plasma. Mean peak 1,2- and 1,3-dinitroglycerin plasma concentrations occur at approximately 15 minutes postdose. The elimination half-life of 1,2- and 1,3-dinitroglycerin is 36 and 32 minutes, respectively. The 1,2- and 1,3‑dinitroglycerin metabolites have been reported to possess approximately 2% and 10%, respectively, of the pharmacological activity of nitroglycerin. Higher plasma concentrations of the dinitro metabolites, along with their nearly 10-fold longer elimination half-lives, may contribute significantly to the duration of pharmacologic effect. Glycerol mononitrate metabolites of nitroglycerin are biologically inactive. Elimination Nitroglycerin plasma concentrations decrease rapidly, with a mean elimination half-life of 2 to 3 minutes. Half-life values range from 1.5 to 7.5 minutes. Clearance (13.6 L/min) greatly exceeds hepatic blood flow. Metabolism is the primary route of drug elimination. Drug interactions Aspirin: Coadministration of nitroglycerin with high dose aspirin (1000 mg) results in increased exposure to nitroglycerin. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of nitroglycerin with high dose aspirin. Tissue-type plasminogen activator (t-PA) : Concomitant administration of t-PA and intravenous nitroglycerin has been shown to reduce plasma levels of t-PA and its thrombolytic effect."],"indications_and_usage":["1 INDICATIONS AND USAGE Nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin sublingual tablets are a nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Tolerance: Excessive use may lead to tolerance. ( 5.1 ) • Hypotension: Severe hypotension may occur. ( 5.2 ) 5.1 Tolerance Excessive use may lead to the development of tolerance. Only the smallest dose required for effective relief of the acute angina attack should be used. A decrease in therapeutic effect of sublingual nitroglycerin may result from use of long-acting nitrates. 5.2 Hypotension Severe hypotension, particularly with upright posture, may occur with small doses of nitroglycerin particularly in patients with constrictive pericarditis, aortic or mitral stenosis, patients who may be volume-depleted, or are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. Symptoms of severe hypotension (nausea, vomiting, weakness, pallor, perspiration and collapse/syncope) may occur even with therapeutic doses. 5.3 Hypertrophic Obstructive Cardiomyopathy Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy. 5.4 Headache Nitroglycerin produces dose-related headaches, especially at the start of nitroglycerin therapy, which may be severe and persist but usually subside with continued use."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal carcinogenesis studies with sublingually administered nitroglycerin have not been performed. Carcinogenicity potential of nitroglycerin was evaluated in rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years. Rats developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At high dose, the incidences of hepatocellular carcinomas in males was 48% and in females was 33%, compared to 0% in untreated controls. Incidences of testicular tumors were 52% vs. 8% in controls. Lifetime dietary administration of up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice. Nitroglycerin was mutagenic in Ames tests performed in 2 different laboratories. Nevertheless, there was no evidence of mutagenicity in an in vivo dominant lethal assay with male rats treated with doses up to about 363 mg/kg/day, PO, or in ex vivo cytogenetic tests in rat and dog cells. In a 3-generation reproduction study, rats received dietary nitroglycerin at doses up to about 434 mg/kg/day for 6 months prior to mating of the F0 generation, with treatment continuing through successive F1 and F2 generations. The high dose was associated with decreased feed intake and body weight gain in both sexes at all matings. No specific effect on the fertility of the F0 generation was seen. Infertility noted in subsequent generations, however, was attributed to increased interstitial cell tissue and aspermatogenesis in the high-dose males. In this 3-generation study, there was no clear evidence of teratogenicity."],"pharmacokinetics_table":["<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 1</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">         Parameter</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Mean Nitroglycerin (SD) Values</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">2 &#xD7; 0.3 mg  </content></paragraph><paragraph><content styleCode=\"bold\">Nitroglycerin Sublingual  Tablets</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">1 </content>&#xD7;<content styleCode=\"bold\"> 0.6 mg  </content></paragraph><paragraph><content styleCode=\"bold\">Nitroglycerin Sublingual  Tablets</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> C<sub>max</sub>, ng/mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.3 (1.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.1 (1.5)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> T<sub>max</sub>, min</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.4 (2.5)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.2 (3.2)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> AUC(0&#x2013;&#x221E;), min</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14.9 (8.2)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14.9 (11.4)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> t&#xBD;, min</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2.8 (1.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2.6 (0.6)</paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). GREENSTONE ® BRAND Distributed by: Greenstone LLC Morgantown, WV 26505 U.S.A. © 2024 Viatris Inc. GST:NITR:R1 Revised: 10/2024"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. Allow tablet to dissolve without swallowing. One additional tablet may be administered every 5 minutes until relief is obtained. No more than three tablets are recommended within a 15-minute period. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. Nitroglycerin sublingual tablets may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack. For patients with xerostomia, a small sip of water prior to placing the tablet under the tongue may help maintain mucosal hydration and aid dissolution of the tablet. Administer nitroglycerin sublingual tablets at rest, preferably in the sitting position. • At the onset of an attack, administer one tablet under the tongue or buccal pouch. One additional tablet may be administered every 5 minutes as needed. No more than 3 total tablets are recommended within a 15 minute period. ( 2 ) • If chest pain persists after three tablets, seek prompt medical attention. ( 2 ) • May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack. ( 2 )"],"spl_product_data_elements":["NITROGLYCERIN nitroglycerin NITROGLYCERIN NITROGLYCERIN LACTOSE MONOHYDRATE GLYCERYL MONOSTEARATE STARCH, CORN CALCIUM STEARATE SILICON DIOXIDE N;3 NITROGLYCERIN nitroglycerin NITROGLYCERIN NITROGLYCERIN LACTOSE MONOHYDRATE GLYCERYL MONOSTEARATE STARCH, CORN CALCIUM STEARATE SILICON DIOXIDE N;4 NITROGLYCERIN nitroglycerin NITROGLYCERIN NITROGLYCERIN LACTOSE MONOHYDRATE GLYCERYL MONOSTEARATE STARCH, CORN CALCIUM STEARATE SILICON DIOXIDE N;6"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Nitroglycerin Sublingual Tablets are supplied as white, round, flat-faced tablets in three strengths: 0.3 mg (Coded with “N” on one side and “3” on the other) 0.4 mg (Coded with “N” on one side and “4” on the other) 0.6 mg (Coded with “N” on one side and “6” on the other) Sublingual tablets, 0.3 mg; 0.4 mg; 0.6 mg ( 3 )"],"spl_patient_package_insert":["Nitroglycerin Sublingual Tablets, USP Read this information carefully before you start nitroglycerin sublingual tablets and each time you refill your prescription. There may be new information. This information does not replace talking with your doctor. If you have any questions about nitroglycerin sublingual tablets , ask your doctor. Your doctor will know if nitroglycerin sublingual tablets are right for you. What are nitroglycerin sublingual tablets? Nitroglycerin sublingual tablets are a type of medicine known as an organic nitrate and is a vasodilating agent. They are used to treat a type of chest pain called angina. What is Angina? Angina is a pain or discomfort that keeps coming back when part of your heart does not get enough blood. Angina feels like a pressing or squeezing pain, usually in your chest under the breastbone. Sometimes you can feel it in your shoulders, arms, neck, jaws, or back. Nitroglycerin sublingual tablets can relieve this pain. Who should not use nitroglycerin sublingual tablets? Do not use nitroglycerin sublingual tablets if you are allergic to organic nitrates (like the active ingredient in nitroglycerin sublingual tablets ). You should not take nitroglycerin sublingual tablets if you have the following conditions: • very recent heart attack • severe anemia • increased pressure in the head Do not take nitroglycerin sublingual tablets with drugs for erectile dysfunction, like VIAGRA ® (sildenafil citrate), CIALIS ® (tadalafil), or LEVITRA ® (vardenafil hydrochloride), as this may lead to extreme lowering of your blood pressure . Do not take nitroglycerin sublingual tablets if you take medicines called guanylate cyclase stimulators which include riociguat, a medicine that treats pulmonary arterial hypertension and chronic‑thromboembolic pulmonary hypertension. What should I tell my doctor before taking nitroglycerin sublingual tablets? Before using nitroglycerin sublingual tablets , tell your doctor if: • You are taking any medicines that are used to treat angina, heart failure, or an irregular heartbeat. • You are taking any medicines that reduce blood pressure. • You are taking any diuretics (water pills). • You are taking medicines that can cause dry mouth such as tricyclic antidepressants (e.g. amitriptyline, desipramine, doxepin), anticholinergic drugs, or any antimuscarinic drugs (e.g. atropine). • You are taking ergotamine or similar drugs for migraine headaches. • You are taking aspirin. • You are taking any medicines for erectile dysfunction. • You are pregnant or plan to become pregnant. • You are breastfeeding. How should I take nitroglycerin sublingual tablets? • Do not chew, crush, or swallow nitroglycerin sublingual tablets . • You should sit down when taking nitroglycerin sublingual tablets and use caution when you stand up. This eliminates the possibility of falling due to lightheadedness or dizziness. • One tablet should be dissolved under the tongue or in the oral cavity at the first sign of chest pain. • The dose may be repeated approximately every 5 minutes, until the chest pain is relieved. • If the pain persists after a total of 3 tablets in a 15-minute period, or is different than you typically experience, call your doctor or seek emergency help. • Nitroglycerin sublingual tablets may be used 5 to 10 minutes prior to activities that might cause chest pain. • You may feel a burning or tingling sensation in your mouth when you take nitroglycerin sublingual tablets . What should I avoid while taking nitroglycerin sublingual tablets? • Do not breastfeed. It is not known if nitroglycerin will pass through your milk. • Do not consume alcohol while taking nitroglycerin sublingual tablets , as this can lower your blood pressure. • Do not start any new prescription or non-prescription medicines or supplements, unless you check with your doctor first. What are the possible side effects of nitroglycerin sublingual tablets? Nitroglycerin sublingual tablets may cause the following side effects: • headache • vertigo (a major symptom of balance disorder) • dizziness • weakness • heart palpitations (unusual awareness of the heartbeat) • low blood pressure upon rising from a seated position • nausea and vomiting • sweating • paleness • fainting • flushing (warm or red condition of your skin) • other skin reactions that may be severe Tell your doctor if you are concerned about any side effects you experience. These are not all the possible side effects of nitroglycerin sublingual tablets . For a complete list, ask your doctor or pharmacist. How do I store nitroglycerin sublingual tablets? Nitroglycerin sublingual tablets should be kept in the original glass container and tightly capped after each use to prevent loss of tablet potency. Store nitroglycerin sublingual tablets at room temperature (between 68° and 77°F). General advice about nitroglycerin sublingual tablets Sometimes doctors will prescribe a medicine for a condition that is not included in the patient information leaflets. Only use nitroglycerin sublingual tablets the way your doctor told you to. Do not give nitroglycerin sublingual tablets to other people, even if they have the same symptoms you have. They may harm them. You can ask your pharmacist or doctor for information about nitroglycerin sublingual tablets , or contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX). GREENSTONE ® BRAND Distributed by: Greenstone LLC Morgantown, WV 26505 U.S.A. The brands listed are trademarks of their respective owners. © 2024 Viatris Inc. GST:PL:NITR:R1 Revised: 10/2024"],"clinical_pharmacology_table":["<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 1</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">         Parameter</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Mean Nitroglycerin (SD) Values</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">2 &#xD7; 0.3 mg  </content></paragraph><paragraph><content styleCode=\"bold\">Nitroglycerin Sublingual  Tablets</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">1 </content>&#xD7;<content styleCode=\"bold\"> 0.6 mg  </content></paragraph><paragraph><content styleCode=\"bold\">Nitroglycerin Sublingual  Tablets</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> C<sub>max</sub>, ng/mL</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.3 (1.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.1 (1.5)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> T<sub>max</sub>, min</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6.4 (2.5)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.2 (3.2)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> AUC(0&#x2013;&#x221E;), min</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14.9 (8.2)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14.9 (11.4)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> t&#xBD;, min</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2.8 (1.1)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2.6 (0.6)</paragraph></td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Limited published data on the use of nitroglycerin are insufficient to determine a drug associated risk of major birth defects or miscarriage. In animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose [see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data No embryotoxic or postnatal development effects were observed with transdermal application in pregnant rabbits and rats at doses up to 80 and 240 mg/kg/day, respectively, at intraperitoneal doses in pregnant rats up to 20 mg/kg/day from gestation day 7-17, and at intravenous doses in pregnant rabbits up to 4 mg/kg/day from gestation day 6-18. 8.2 Lactation Risk Summary Sublingual nitroglycerin has not been studied in lactating women. It is not known if nitroglycerin is present in human milk or if nitroglycerin has effects on milk production. 8.4 Pediatric Use The safety and effectiveness of nitroglycerin in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of nitroglycerin sublingual tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL – 0.3 mg ALWAYS DISPENSE WITH PATIENT PACKAGE INSERT NDC 59762-4921-1 100 Sublingual Tablets nitroglycerin sublingual tablets, USP 0.3 mg/tablet Rx only Store at Controlled Room Temperature 20°-25°C (68°-77°F) [see USP]. DOSAGE AND USE: See accompanying prescribing information. Each tablet contains 0.3 mg nitroglycerin. Keep this and all drugs out of the reach of children. Please note – You may feel a \"burning or tingling\" sensation at the site of tablet placement. Lack of \"burning or tingling\" in your mouth does not indicate failure of nitroglycerin release. If the pain persists after a total of 3 tablets in a 15-minute period, or is different than you typically experience, prompt medical attention is recommended. Warning – Close tightly immediately after each use to prevent loss of potency. Keep these tablets in the original container. Do not crush, chew, or swallow nitroglycerin Tablets. GST:4921:100C:R1 Distributed by: Greenstone LLC Morgantown, WV 26505 U.S.A. © 2024 Viatris Inc. Nitroglycerin Sublingual Tablets, USP 0.3 mg Bottle Labels","PRINCIPAL DISPLAY PANEL – 0.4 mg ALWAYS DISPENSE WITH PATIENT PACKAGE INSERT NDC 59762-3304-1 100 Sublingual Tablets nitroglycerin sublingual tablets, USP 0.4 mg/tablet Rx only Store at Controlled Room Temperature 20°-25°C (68°-77°F) [see USP]. DOSAGE AND USE: See accompanying prescribing information. Each tablet contains 0.4 mg nitroglycerin. Keep this and all drugs out of the reach of children. Please note – You may feel a \"burning or tingling\" sensation at the site of tablet placement. Lack of \"burning or tingling\" in your mouth does not indicate failure of nitroglycerin release. If the pain persists after a total of 3 tablets in a 15-minute period, or is different than you typically experience, prompt medical attention is recommended. Warning – Close tightly immediately after each use to prevent loss of potency. Keep these tablets in the original container. Do not crush, chew, or swallow nitroglycerin Tablets. GST:3304:1:100C:R1 Distributed by: Greenstone LLC Morgantown, WV 26505 U.S.A. © 2024 Viatris Inc. Nitroglycerin Sublingual Tablets, USP 0.4 mg Bottle Labels","PRINCIPAL DISPLAY PANEL – 0.6 mg ALWAYS DISPENSE WITH PATIENT PACKAGE INSERT NDC 59762-0489-1 100 Sublingual Tablets nitroglycerin sublingual tablets, USP 0.6 mg/tablet Rx only Store at Controlled Room Temperature 20°-25°C (68°-77°F) [see USP]. DOSAGE AND USE: See accompanying prescribing information. Each tablet contains 0.6 mg nitroglycerin. Keep this and all drugs out of the reach of children. Please note – You may feel a \"burning or tingling\" sensation at the site of tablet placement. Lack of \"burning or tingling\" in your mouth does not indicate failure of nitroglycerin release. If the pain persists after a total of 3 tablets in a 15-minute period, or is different than you typically experience, prompt medical attention is recommended. Warning – Close tightly immediately after each use to prevent loss of potency. Keep these tablets in the original container. Do not crush, chew, or swallow nitroglycerin Tablets. GST:0489:100C:R1 Distributed by: Greenstone LLC Morgantown, WV 26505 U.S.A. © 2024 Viatris Inc. Nitroglycerin Sublingual Tablets, USP 0.6 mg Bottle Labels"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal carcinogenesis studies with sublingually administered nitroglycerin have not been performed. Carcinogenicity potential of nitroglycerin was evaluated in rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years. Rats developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At high dose, the incidences of hepatocellular carcinomas in males was 48% and in females was 33%, compared to 0% in untreated controls. Incidences of testicular tumors were 52% vs. 8% in controls. Lifetime dietary administration of up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice. Nitroglycerin was mutagenic in Ames tests performed in 2 different laboratories. Nevertheless, there was no evidence of mutagenicity in an in vivo dominant lethal assay with male rats treated with doses up to about 363 mg/kg/day, PO, or in ex vivo cytogenetic tests in rat and dog cells. In a 3-generation reproduction study, rats received dietary nitroglycerin at doses up to about 434 mg/kg/day for 6 months prior to mating of the F0 generation, with treatment continuing through successive F1 and F2 generations. The high dose was associated with decreased feed intake and body weight gain in both sexes at all matings. No specific effect on the fertility of the F0 generation was seen. Infertility noted in subsequent generations, however, was attributed to increased interstitial cell tissue and aspermatogenesis in the high-dose males. In this 3-generation study, there was no clear evidence of teratogenicity."]},"tags":[{"label":"Nitrate Vasodilator","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Atrial natriuretic peptide receptor 1","category":"target"},{"label":"NPR1","category":"gene"},{"label":"GUCY1A2","category":"gene"},{"label":"GUCY1A3","category":"gene"},{"label":"C01DA02","category":"atc"},{"label":"Sublingual","category":"route"},{"label":"Oral","category":"route"},{"label":"Transdermal","category":"route"},{"label":"Aerosol","category":"form"},{"label":"Capsule","category":"form"},{"label":"Film","category":"form"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Angina Pectoris Prevention","category":"indication"},{"label":"Angina pectoris","category":"indication"},{"label":"Left ventricular cardiac dysfunction","category":"indication"},{"label":"Perioperative hypertension","category":"indication"},{"label":"Fougera","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Explosive Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":2119.564,"date":"","count":2128,"signal":"Myocardial infarction","source":"DrugCentral FAERS","actionTaken":"Reported 2,128 times (LLR=2120)"},{"llr":999.208,"date":"","count":885,"signal":"Coronary artery disease","source":"DrugCentral FAERS","actionTaken":"Reported 885 times (LLR=999)"},{"llr":867.796,"date":"","count":846,"signal":"Acute myocardial infarction","source":"DrugCentral FAERS","actionTaken":"Reported 846 times (LLR=868)"},{"llr":853.452,"date":"","count":1177,"signal":"Cardiac failure congestive","source":"DrugCentral FAERS","actionTaken":"Reported 1,177 times (LLR=853)"},{"llr":839.358,"date":"","count":725,"signal":"Angina pectoris","source":"DrugCentral FAERS","actionTaken":"Reported 725 times (LLR=839)"},{"llr":779.142,"date":"","count":708,"signal":"Orthostatic hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 708 times (LLR=779)"},{"llr":713.684,"date":"","count":402,"signal":"Sedation complication","source":"DrugCentral FAERS","actionTaken":"Reported 402 times (LLR=714)"},{"llr":682.206,"date":"","count":420,"signal":"Creatinine renal clearance decreased","source":"DrugCentral FAERS","actionTaken":"Reported 420 times (LLR=682)"},{"llr":676.902,"date":"","count":1570,"signal":"Chest pain","source":"DrugCentral FAERS","actionTaken":"Reported 1,570 times (LLR=677)"},{"llr":589.76,"date":"","count":1903,"signal":"Hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 1,903 times (LLR=590)"},{"llr":514.643,"date":"","count":445,"signal":"Blood calcium decreased","source":"DrugCentral FAERS","actionTaken":"Reported 445 times (LLR=515)"},{"llr":480.505,"date":"","count":321,"signal":"Angina unstable","source":"DrugCentral FAERS","actionTaken":"Reported 321 times (LLR=481)"},{"llr":429.066,"date":"","count":509,"signal":"Sedation","source":"DrugCentral FAERS","actionTaken":"Reported 509 times (LLR=429)"},{"llr":427.235,"date":"","count":597,"signal":"Cognitive disorder","source":"DrugCentral FAERS","actionTaken":"Reported 597 times (LLR=427)"},{"llr":388.41,"date":"","count":697,"signal":"Balance disorder","source":"DrugCentral FAERS","actionTaken":"Reported 697 times (LLR=388)"}],"drugInteractions":[{"url":"/drug/sildenafil","drug":"sildenafil","action":"Avoid combination","effect":"May interact with Nitroglycerin, Sildenafil Citrate","source":"DrugCentral","drugSlug":"sildenafil"},{"url":"/drug/tadalafil","drug":"tadalafil","action":"Avoid combination","effect":"May interact with Nitroglycerin, Tadalafil","source":"DrugCentral","drugSlug":"tadalafil"},{"url":"/drug/vardenafil","drug":"vardenafil","action":"Avoid combination","effect":"May interact with Nitroglycerin, Vardenafil","source":"DrugCentral","drugSlug":"vardenafil"}],"commonSideEffects":[{"effect":"Syncope","drugRate":"reported","severity":"unknown"},{"effect":"Marked sensitivity to the hypotensive effects of nitrates","drugRate":"reported","severity":"unknown"},{"effect":"Flushing","drugRate":"reported","severity":"unknown"},{"effect":"Drug rash","drugRate":"reported","severity":"unknown"},{"effect":"Exfoliative dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Weakness","drugRate":"reported","severity":"unknown"},{"effect":"Diaphoresis","drugRate":"reported","severity":"unknown"},{"effect":"Pallor","drugRate":"reported","severity":"unknown"},{"effect":"Collapse","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Vertigo","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Palpitation","drugRate":"reported","severity":"unknown"}],"contraindications":["Use of PDE-5 inhibitors (e.g., avanafil, sildenafil, tadalafil, vardenafil) or sGC stimulators (e.g., riociguat) due to risk of severe hypotension, syncope, or myocardial ischemia.","Severe anemia due to potential exacerbation by nitroglycerin.","Increased intracranial pressure (e.g., cerebral hemorrhage, traumatic brain injury) due to risk of precipitation or aggravation.","Hypersensitivity to nitroglycerin, other nitrates or nitrites, or any excipient.","Circulatory failure and shock."],"specialPopulations":{"Pregnancy":"Nitroglycerin should be given to pregnant woman only if clearly needed. Limited published data on the use of nitroglycerin are insufficient to determine drug associated risk of major birth defects or miscarriage. In animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose.","Geriatric use":"Clinical studies of transdermal nitroglycerin did not include sufficient information to determine whether subjects 65 years and older respond differently from younger subjects. Additional clinical data from the published literature indicate that the elderly demonstrate increased sensitivity to nitrates, which may result in hypotension and increased risk of falling. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.","Paediatric use":"Safety and effectiveness in children have not been established."}},"trials":[],"aliases":["Rectogesic","GTN","MED2005","Topical GTN treatment","Percutol"],"company":"Fougera","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2032-03-11","territory":"US","patentNumber":"9101592"},{"source":"FDA Orange Book via DrugCentral","expires":"2029-03-12","territory":"US","patentNumber":"7872049"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=glyceryl trinitrate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:43:59.373807+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:43:59.373707+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Glyceryl Trinitrate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:44:06.430921+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:44:04.606691+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=glyceryl trinitrate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:44:05.140361+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:57.885259+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:57.885298+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:57.885307+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:41.537421+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Soluble guanylate cyclase activator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:44:06.430843+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL730/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:44:06.080211+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:44:50.804594+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021134","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:57.885311+00:00"}},"allNames":"nitroglycerin","offLabel":[],"synonyms":["nitroglycerin","nitroglycerine","nitroglycerol","propanetriol trinitrate","trinitroglycerin","trinitroglycerol","glyceryl trinitrate"],"timeline":[{"date":"1981-05-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (Fougera)"}],"aiSummary":"Nitroglycerin, also known as glyceryl trinitrate, is a small molecule nitrate vasodilator developed by FOUGERA and currently owned by the same company. It targets the atrial natriuretic peptide receptor 1 and is FDA-approved for the prevention and treatment of angina pectoris, left ventricular cardiac dysfunction, and perioperative hypertension. Nitroglycerin works by relaxing vascular smooth muscle, leading to vasodilation and reduced blood pressure. As a nitrate vasodilator, it is off-patent and has a bioavailability of 1%. Key safety considerations include its short half-life of 4.5 hours and potential for tolerance development.","approvals":[{"date":"1981-05-28","orphan":false,"company":"FOUGERA","regulator":"FDA"}],"brandName":"Nitroglycerin","ecosystem":[{"indication":"Angina Pectoris Prevention","otherDrugs":[{"name":"isosorbide dinitrate","slug":"isosorbide-dinitrate","company":"Astrazeneca"},{"name":"isosorbide mononitrate","slug":"isosorbide-mononitrate","company":""}],"globalPrevalence":112000000},{"indication":"Angina pectoris","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atenolol","slug":"atenolol","company":"Alvogen Ipco Sarl"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"bepridil","slug":"bepridil","company":""}],"globalPrevalence":112000000},{"indication":"Left ventricular cardiac dysfunction","otherDrugs":[{"name":"captopril","slug":"captopril","company":"Par Pharm"},{"name":"carvedilol","slug":"carvedilol","company":"Smithkline Beecham"},{"name":"ramipril","slug":"ramipril","company":"King Pharms"},{"name":"trandolapril","slug":"trandolapril","company":"Abbvie"}],"globalPrevalence":null},{"indication":"Perioperative hypertension","otherDrugs":[{"name":"esmolol","slug":"esmolol","company":"Baxter Hlthcare"}],"globalPrevalence":1280000000}],"mechanism":{"target":"guanylate cyclase","novelty":"Follow-on","targets":[{"gene":"NPR1","source":"DrugCentral","target":"Atrial natriuretic peptide receptor 1","protein":"Atrial natriuretic peptide receptor 1"},{"gene":"GUCY1A2","source":"DrugCentral","target":"Soluble guanylate cyclase","protein":"Guanylate cyclase soluble subunit alpha-2"},{"gene":"GUCY1A3","source":"DrugCentral","target":"Soluble guanylate cyclase","protein":"Guanylate cyclase soluble subunit alpha-3"},{"gene":"GUCY1B2","source":"DrugCentral","target":"Soluble guanylate cyclase","protein":"Guanylate cyclase soluble subunit beta-2"},{"gene":"GUCY1B3","source":"DrugCentral","target":"Soluble guanylate cyclase","protein":"Guanylate cyclase soluble subunit beta-1"}],"modality":"Small Molecule","drugClass":"Nitrate Vasodilator [EPC]","explanation":"Nitroglycerin works by forming nitric oxide, which activates an enzyme called guanylate cyclase. This activation increases the levels of cyclic GMP in smooth muscle and other tissues, causing the muscles to relax and blood vessels to widen, reducing blood pressure and improving blood flow.","oneSentence":"Nitroglycerin forms nitric oxide, activating guanylate cyclase and increasing cyclic GMP, leading to smooth muscle relaxation and vasodilation.","technicalDetail":"Nitroglycerin forms free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nitroglycerin","title":"Nitroglycerin","extract":"Nitroglycerin (NG), also known as trinitroglycerol (TNG), nitro, glyceryl trinitrate (GTN), or 1,2,3-trinitroxypropane, is a dense, colorless or pale yellow, oily, explosive liquid most commonly produced by nitrating glycerol with white fuming nitric acid under conditions appropriate to the formation of the nitric acid ester. Chemically, the substance is a nitrate ester rather than a nitro compound, but the traditional name is retained. Discovered in 1846 by Ascanio Sobrero, nitroglycerin has been used as an active ingredient in the manufacture of explosives, namely dynamite, and as such it is employed in the construction, demolition, and mining industries. It is combined with nitrocellulose to form double-based smokeless powder, used as a propellant in artillery and firearms since the 1880s.","wiki_history":"== History ==\nthumb|left|[[Alfred Nobel's patent application from 1864.]]\n\nNitroglycerin was the first practical explosive produced that was stronger than black powder. It was synthesized by the Italian chemist Ascanio Sobrero in 1846, working under Théophile-Jules Pelouze at the University of Turin. Sobrero initially called his discovery \"pyroglycerin\" and warned vigorously against its use as an explosive.\n\nNitroglycerin was adopted as a commercially useful explosive by Alfred Nobel, who experimented with safer ways to handle the dangerous compound after his younger brother, Emil Oskar Nobel, and several factory workers were killed in an explosion at the Nobels' armaments factory in 1864 in Heleneborg, Sweden.\n\nOne year later, Nobel founded Alfred Nobel and Company in Germany and built an isolated factory in the Krümmel hills of Geesthacht near Hamburg. This business exported a liquid combination of nitroglycerin and gunpowder called \"Blasting Oil\", but this was extremely unstable and difficult to handle, as evidenced in numerous catastrophes. The buildings of the Krümmel factory were destroyed twice.\n\nIn April 1866, several crates of nitroglycerin were shipped to California, three of which were destined for the Central Pacific Railroad, which planned to experiment with it as a blasting explosive to expedite the construction of the  Summit Tunnel through the Sierra Nevada Mountains. One of the remaining crates exploded, destroying a Wells Fargo company office in San Francisco and killing 15 people. This led to a complete ban on the transportation of liquid nitroglycerin in California. The on-site manufacture of nitroglycerin was thus required for the remaining hard-rock drilling and blasting required for the completion of the First transcontinental railroad in North America.\n\nOn Christmas Day 1867, an attempt to dispose of nine canisters of Blasting Oil that had been illegally stored at the White Swan Inn in the centre of Newcastle upon Tyne resulted in an explosio"},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-05-28, FOUGERA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1952","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=glyceryl%20trinitrate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=glyceryl trinitrate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Nitroglycerin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T13:49:15.945496","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:44:51.740958+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"isosorbide dinitrate","drugSlug":"isosorbide-dinitrate","fdaApproval":"1968-01-16","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isosorbide mononitrate","drugSlug":"isosorbide-mononitrate","fdaApproval":"1991-12-30","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"glyceryl trinitrate","indications":{"approved":[{"name":"Angina Pectoris Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":112000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Angina pectoris","source":"DrugCentral","snomedId":194828000,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":null,"globalPrevalence":112000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Left ventricular cardiac dysfunction","source":"DrugCentral","snomedId":429589006,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Perioperative hypertension","source":"DrugCentral","snomedId":434711000124103,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[{"name":"Acute coronary syndrome","source":"DrugCentral","drugName":"glyceryl trinitrate","evidenceCount":243,"evidenceLevel":"strong"},{"name":"Anal fissure","source":"DrugCentral","drugName":"glyceryl trinitrate","evidenceCount":296,"evidenceLevel":"strong"},{"name":"Decompensated cardiac failure","source":"DrugCentral","drugName":"glyceryl trinitrate","evidenceCount":107,"evidenceLevel":"strong"},{"name":"Extravasation injury","source":"DrugCentral","drugName":"glyceryl trinitrate","evidenceCount":23,"evidenceLevel":"moderate"},{"name":"Hypertensive urgency","source":"DrugCentral","drugName":"glyceryl trinitrate","evidenceCount":58,"evidenceLevel":"strong"},{"name":"Myocardial infarction","source":"DrugCentral","drugName":"glyceryl trinitrate","evidenceCount":2070,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"isosorbide-dinitrate","brandName":"isosorbide dinitrate","genericName":"isosorbide dinitrate","approvalYear":"1968","relationship":"same-class"},{"drugId":"isosorbide-mononitrate","brandName":"isosorbide mononitrate","genericName":"isosorbide mononitrate","approvalYear":"1991","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07480876","phase":"NA","title":"Glyceryl Trinitrate Gel Phonophoresis on Planter Fasciiatis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-04-30","conditions":["Planter Fasciitis"],"enrollment":80,"completionDate":"2026-11-30"},{"nctId":"NCT06301880","phase":"PHASE3","title":"Effect of Topically-applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow","status":"COMPLETED","sponsor":"Damascus University","startDate":"2022-01-01","conditions":["Internal Mammary Artery Syndrome","Vasodilation"],"enrollment":46,"completionDate":"2023-01-31"},{"nctId":"NCT03304496","phase":"PHASE4","title":"Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.","status":"SUSPENDED","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2018-03-30","conditions":["Coronary Artery Disease"],"enrollment":1400,"completionDate":"2026-03-31"},{"nctId":"NCT06682260","phase":"PHASE4","title":"Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure","status":"COMPLETED","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2025-02-01","conditions":["Acute Heart Failure (AHF)"],"enrollment":21,"completionDate":"2025-11-30"},{"nctId":"NCT06408597","phase":"NA","title":"Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazmy Edward Seif","startDate":"2024-05-12","conditions":["Prostate Cancer","Bladder Cancer","Surgery","Renal Impairment","Renal Injury, Acute"],"enrollment":90,"completionDate":"2026-05"},{"nctId":"NCT03785574","phase":"NA","title":"Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2018-12-24","conditions":["Hydatidiform Mole","Gestational Trophoblastic Neoplasia"],"enrollment":30,"completionDate":"2030-09-01"},{"nctId":"NCT07431294","phase":"PHASE1","title":"A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-07","conditions":["Stable Coronary Artery Disease"],"enrollment":36,"completionDate":"2026-12-04"},{"nctId":"NCT07440121","phase":"NA","title":"Optimized Strict Fluid Management Helps Improve Endpoints After Liver Dissection","status":"NOT_YET_RECRUITING","sponsor":"Zhihong LU","startDate":"2026-04-02","conditions":["Anesthesia","Surgery"],"enrollment":90,"completionDate":"2027-02-02"},{"nctId":"NCT06788275","phase":"NA","title":"Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria y Biomédica de Alicante","startDate":"2024-11-01","conditions":["Percutaneous Coronary Intervention (PCI)","Acute Myocardial Infarction","Angina (Stable)","Unstable Angina Pectoris","Cardiorespiratory Fitness","Ischaemic Heart Diseases"],"enrollment":132,"completionDate":"2027-11"},{"nctId":"NCT06273293","phase":"NA","title":"Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2024-05-31","conditions":["Coronary Disease"],"enrollment":150,"completionDate":"2027-01-20"},{"nctId":"NCT07391501","phase":"PHASE4","title":"Nitroglycerin Ointment for Pain Relief After Endoscopic Hemorrhoid Band Ligation","status":"NOT_YET_RECRUITING","sponsor":"Ying Zhu","startDate":"2026-02-01","conditions":["Internal Hemorrhoids","Postoperative Pain After Endoscopic Rubber Band Ligation"],"enrollment":68,"completionDate":"2028-11-30"},{"nctId":"NCT07346677","phase":"PHASE2","title":"Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel","status":"NOT_YET_RECRUITING","sponsor":"University of Basrah","startDate":"2026-02-20","conditions":["Cancer","Chemotherapy"],"enrollment":190,"completionDate":"2026-04-20"},{"nctId":"NCT06783296","phase":"NA","title":"Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2026-01-01","conditions":["Hypertension","Renal Denervation Therapy"],"enrollment":124,"completionDate":"2028-07-31"},{"nctId":"NCT07306572","phase":"NA","title":"Loupe-Assisted Varicocelectomy With Nitroglycerin Instillation Versus Microscopic Varicocelectomy","status":"COMPLETED","sponsor":"Fayoum University Hospital","startDate":"2023-05-01","conditions":["Nitroglycerine Instillation in Loop-assisted Varicocelectomy","Microscopic Varicocelectomy"],"enrollment":60,"completionDate":"2024-06-01"},{"nctId":"NCT05687669","phase":"PHASE4","title":"Comparison Between the Use of Phentolamine Versus Glyceryl Trinitrate for Their Effect on Renal Function in Pre-eclampsia Patients in ICU","status":"COMPLETED","sponsor":"Assiut University","startDate":"2023-01-12","conditions":["Pre-Eclampsia; Complicating Pregnancy","Pre-eclampsia Aggravated"],"enrollment":170,"completionDate":"2023-06-12"},{"nctId":"NCT03135769","phase":"PHASE2","title":"Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-02-21","conditions":["Gestational Trophoblastic Neoplasias (GTN)"],"enrollment":24,"completionDate":"2021-03-17"},{"nctId":"NCT07004764","phase":"PHASE1","title":"Enhancing Wound Perfusion in High-Risk Lower Extremity Orthopaedic Surgery: A Study on Nitropaste Using Intraoperative SPY Imaging.","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03","conditions":["Achilles Tendon Repairs/Reconstructions","Pilon Fracture of Tibia","Tibial Plateau Fracture","Ankle Fracture (Bimalleolar Equivalent, Bimalleolar, or Trimalleolar)","Calcaneus Fractures","Talus Fracture","Wound Infection Deep","Wound Infection Post-Traumatic","Wound Dehiscence, Surgical"],"enrollment":15,"completionDate":"2027-12"},{"nctId":"NCT07083063","phase":"PHASE4","title":"Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis","status":"RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-09-15","conditions":["Pancreatitis"],"enrollment":440,"completionDate":"2027-07-31"},{"nctId":"NCT07214129","phase":"NA","title":"Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":["Pulmonary Arterial Hypertension"],"enrollment":20,"completionDate":"2024-03-01"},{"nctId":"NCT07197463","phase":"NA","title":"The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-10-10","conditions":["Coronary Disease","Sarcopenia"],"enrollment":100,"completionDate":"2026-11-10"},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":["Chronic Obstructive Pulmonary Disease","Pulmonary Artery Hypertension","Heart Failure","Hypertension"],"enrollment":420,"completionDate":"2026-08"},{"nctId":"NCT07159334","phase":"NA","title":"\"Lignocaine vs GTN Ointment for Postoperative Pain After Hemorrhoidectomy\")","status":"RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-08-02","conditions":["Hemorrhoid","Postoperative Pain"],"enrollment":64,"completionDate":"2025-12"},{"nctId":"NCT05793567","phase":"","title":"A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-08","conditions":["Myocardial Infarction","Coronary Microvascular Disease"],"enrollment":52,"completionDate":"2027-04"},{"nctId":"NCT02425566","phase":"PHASE1","title":"Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2015-04","conditions":["Hypertension"],"enrollment":12,"completionDate":"2026-08"},{"nctId":"NCT03026101","phase":"NA","title":"Understanding the Pathophysiology of Migraine Pain","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2017-01","conditions":["Migraine Disorders","Migraine, Classic","Migraine Without Aura"],"enrollment":4,"completionDate":"2025-04-24"},{"nctId":"NCT05711199","phase":"EARLY_PHASE1","title":"Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-01","conditions":["Brown Adipose Tissue"],"enrollment":30,"completionDate":"2025-06-30"},{"nctId":"NCT07074834","phase":"NA","title":"Metoprolol and Trimetazidine for Coronary Heart Disease With Angina","status":"COMPLETED","sponsor":"Shiyan City Renmin Hospital","startDate":"2021-02-01","conditions":["Coronary Heart Disease (CHD)"],"enrollment":102,"completionDate":"2022-12-31"},{"nctId":"NCT05741229","phase":"NA","title":"The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":["Persistent Pulmonary Hypertension of the Newborn","Echocardiography","Respiratory Disease"],"enrollment":80,"completionDate":"2025-01-20"},{"nctId":"NCT07044232","phase":"PHASE4","title":"NICardipine for Fast Achievement of Systolic BP Targets in ICH","status":"NOT_YET_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-10-01","conditions":["Intracerebral Haemorrhage"],"enrollment":88,"completionDate":"2027-12-31"},{"nctId":"NCT00823563","phase":"","title":"Evaluation of Patients With Non-obstructive Coronary Arteries","status":"RECRUITING","sponsor":"Stanford University","startDate":"2007-06","conditions":["Chest Pain","Ischemia"],"enrollment":2000,"completionDate":"2047-06"},{"nctId":"NCT06896903","phase":"NA","title":"Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2025-05-21","conditions":["ANOCA - Angina With Non-obstructive Coronary Arteries","INOCA (Ischemia With Non Obstructive Coronary Artery Disease)"],"enrollment":50,"completionDate":"2026-06-01"},{"nctId":"NCT05952011","phase":"NA","title":"Effect of Stellate Ganglion Block on Internal Mammary Artery Dynamics","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-08-08","conditions":["Anesthesia"],"enrollment":70,"completionDate":"2025-02-10"},{"nctId":"NCT05855954","phase":"NA","title":"Application of CLCVP Technique in Early Intervention of CSA-AKI","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-05-01","conditions":["Acute Kidney Injury"],"enrollment":200,"completionDate":"2025-12-30"},{"nctId":"NCT06859554","phase":"PHASE4","title":"Efficacy and Safety of GTN vs. Nifedipine in Acute Anal Fissure: A Clinical Trial","status":"COMPLETED","sponsor":"Hafiz Muhammad Hamza","startDate":"2025-03-17","conditions":["Acute Anal Fissure","Anal Pain","Anorectal Disorders","Sphincter Spasm"],"enrollment":110,"completionDate":"2025-05-10"},{"nctId":"NCT01996436","phase":"PHASE4","title":"The Intra-arterial Vasospasm Trial","status":"TERMINATED","sponsor":"Peng Roc Chen, MD","startDate":"2016-08-29","conditions":["Cerebral Vasospasm"],"enrollment":92,"completionDate":"2024-08-12"},{"nctId":"NCT06726109","phase":"","title":"The FOCUS-ADHF Registry","status":"RECRUITING","sponsor":"ASL Città di Torino","startDate":"2025-04-27","conditions":["Acute Heart Failure With Reduced Ejection Fraction","Decompensation; Heart, Congestive","Regurgitation, Mitral"],"enrollment":600,"completionDate":"2030-08"},{"nctId":"NCT03376555","phase":"PHASE1,PHASE2","title":"Cheese Consumption and Human Microvascular Function","status":"COMPLETED","sponsor":"Lacy Alexander","startDate":"2017-07-01","conditions":["Microvascular Dysfunction"],"enrollment":13,"completionDate":"2021-03-01"},{"nctId":"NCT06956924","phase":"NA","title":"Abdominal Aortic Calcium and CAD-RADS 2.0","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-06-01","conditions":["Coronary Artery Disease (CAD)"],"enrollment":68,"completionDate":"2023-05-31"},{"nctId":"NCT06238882","phase":"NA","title":"Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-02-23","conditions":["Non-small Cell Lung Cancer","Brain Metastases","EGFR Gene Mutation"],"enrollment":74,"completionDate":"2026-02-15"},{"nctId":"NCT05443061","phase":"NA","title":"Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Children","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2022-09-08","conditions":["Arterial Line","Ischemia"],"enrollment":200,"completionDate":"2025-03-24"},{"nctId":"NCT05031520","phase":"","title":"PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2021-07-12","conditions":["Non-Obstructive Coronary Atherosclerosis"],"enrollment":32,"completionDate":"2024-12-31"},{"nctId":"NCT03974412","phase":"NA","title":"Syncope Trial to Understand Tilt Testing Early or Recorders Study","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2019-05-28","conditions":["Syncope"],"enrollment":40,"completionDate":"2024-12-31"},{"nctId":"NCT06925763","phase":"NA","title":"Effect of Nitroglycerin Hydrogel on Repairing Critical Bone Defects","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2025-04-01","conditions":["Bone Regeneration","Periodontal Bone Loss","Healing Fracture of Bone"],"enrollment":33,"completionDate":"2025-08-01"},{"nctId":"NCT06912139","phase":"PHASE3","title":"Topical Nitroglycerine for Prevention of Radial Artery Spasm","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy \"Victor Babes\" Timisoara","startDate":"2023-04-01","conditions":["Radial Artery Spasm"],"enrollment":100,"completionDate":"2023-06-30"},{"nctId":"NCT02714205","phase":"PHASE2","title":"Flushing Reduction Associated With Nitrates","status":"COMPLETED","sponsor":"Alison Huang, MD","startDate":"2017-04-24","conditions":["Menopausal Hot Flashes"],"enrollment":141,"completionDate":"2022-04-05"},{"nctId":"NCT06823843","phase":"PHASE4","title":"The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow","status":"COMPLETED","sponsor":"VZW Cardiovascular Research Center Aalst","startDate":"2024-07-01","conditions":["Coronary Arterial Disease (CAD)","Angina (Stable)"],"enrollment":40,"completionDate":"2024-09-30"},{"nctId":"NCT06900699","phase":"","title":"Clinicopathological Features , Outcomes and Prognostic Factors of High Risk Patients of Gestational Trophoblastic Neoplasia","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-04","conditions":["Gestational Trophoblastic Neoplasias (GTN)"],"enrollment":42,"completionDate":"2027-04"},{"nctId":"NCT05393882","phase":"","title":"Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency","status":"WITHDRAWN","sponsor":"Chinese University of Hong Kong","startDate":"2025-09","conditions":["Coronary Artery Disease","Bypass Graft Stenosis","Dyslipidemias","Bypass Graft Occlusion","Coronary Bypass Graft Stenosis","Coronary Artery Stenosis","Hyperlipidemia","Hypercholesterolemia"],"enrollment":0,"completionDate":"2027-12-31"},{"nctId":"NCT06169644","phase":"","title":"The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2024-05-15","conditions":["Gestational Trophoblastic Neoplasia"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT03095313","phase":"PHASE2","title":"18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-07-23","conditions":["Aortic Stenosis"],"enrollment":20,"completionDate":"2024-02-16"},{"nctId":"NCT06028672","phase":"NA","title":"Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-12","conditions":["Gestational Trophoblastic Neoplasia"],"enrollment":40,"completionDate":"2025-08"},{"nctId":"NCT02115724","phase":"NA","title":"Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Augusta University","startDate":"2014-04","conditions":["Cardiovascular Disease"],"enrollment":74,"completionDate":"2027-01"},{"nctId":"NCT06785337","phase":"PHASE2,PHASE3","title":"\"The Effect of Inhaled Nitroglycerin for COPD Patients","status":"RECRUITING","sponsor":"Beni-Suef University","startDate":"2025-02-01","conditions":["COPD","COPD III/IV"],"enrollment":40,"completionDate":"2025-12-01"},{"nctId":"NCT06020755","phase":"PHASE2","title":"Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-12","conditions":["Gestational Trophoblastic Neoplasia"],"enrollment":17,"completionDate":"2025-08"},{"nctId":"NCT05776810","phase":"NA","title":"Syncope Trial to Understand Tilt Testing or ECG Recording Tenth Prevention of Syncope Trial","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-05-01","conditions":["Syncope"],"enrollment":144,"completionDate":"2026-12-31"},{"nctId":"NCT03158532","phase":"PHASE3","title":"Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin","status":"COMPLETED","sponsor":"Instituto de Cardiologia de Santa Catarina","startDate":"2017-07-06","conditions":["Injury of Radial Artery"],"enrollment":2040,"completionDate":"2021-11-01"},{"nctId":"NCT05635851","phase":"PHASE2","title":"NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI","status":"NOT_YET_RECRUITING","sponsor":"Simon Fraser University","startDate":"2025-09","conditions":["Spinal Cord Injuries","Autonomic Dysreflexia"],"enrollment":26,"completionDate":"2026-02"},{"nctId":"NCT03302910","phase":"NA","title":"Short Stay Unit vs Hospitalization in Acute Heart Failure","status":"COMPLETED","sponsor":"Indiana University","startDate":"2017-12-06","conditions":["Acute Heart Failure"],"enrollment":194,"completionDate":"2021-07-22"},{"nctId":"NCT05043610","phase":"PHASE3","title":"MSCs for Prevention of MI-induced HF","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2021-09-15","conditions":["Myocardial Infarction, Acute","Myocardial Infarction First","Myocardial Infarction, Anterior Wall","Cardiac Remodeling, Ventricular","STEMI","Regenerative Medicine","Heart Failure"],"enrollment":420,"completionDate":"2024-11-01"},{"nctId":"NCT03193294","phase":"NA","title":"CORonary MICrovascular Angina (CorMicA)","status":"COMPLETED","sponsor":"NHS National Waiting Times Centre Board","startDate":"2016-11-07","conditions":["Angina, Stable","Coronary Vasospasm","Coronary Circulation","Coronary Syndrome","Microvascular Angina","Coronary Disease"],"enrollment":151,"completionDate":"2019-11-06"},{"nctId":"NCT03477890","phase":"NA","title":"Coronary Microvascular Function and CT Coronary Angiography (CorCTCA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NHS National Waiting Times Centre Board","startDate":"2017-08-31","conditions":["Angina, Stable","Angina Pectoris, Variant","Microvascular Angina"],"enrollment":250,"completionDate":"2033-08-31"},{"nctId":"NCT06637956","phase":"NA","title":"The Effect of Intranasally Administered Nitroglycerin on Hemodynamic Response to Laryngoscopy and Intubation Among Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2024-01-01","conditions":["Coronary Artery Bypass Grafting"],"enrollment":58,"completionDate":"2024-06-30"},{"nctId":"NCT03259165","phase":"PHASE2","title":"Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial","status":"TERMINATED","sponsor":"Indiana University","startDate":"2017-12-14","conditions":["Heart Failure","Heart Failure Acute","Acute Cardiac Failure","Acute Cardiac Pulmonary Edema"],"enrollment":52,"completionDate":"2021-12-31"},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":["Myocardial Infarction With Non-Obstructive Coronary Arteries"],"enrollment":120,"completionDate":"2025-07"},{"nctId":"NCT06509321","phase":"NA","title":"Comparison Between Loupe-Assisted Varicocelectomy With Nitroglycerin Instillation and Microscopic Varicocelectomy","status":"COMPLETED","sponsor":"Fayoum University Hospital","startDate":"2023-05-01","conditions":["Varicocele"],"enrollment":60,"completionDate":"2024-05-01"},{"nctId":"NCT03689946","phase":"PHASE3","title":"Effect of Evolocumab on Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-03-19","conditions":["Cardiovascular Disease","Hyperlipidemia"],"enrollment":55,"completionDate":"2023-05-30"},{"nctId":"NCT04972123","phase":"PHASE2","title":"The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2021-07-20","conditions":["Syncope, Vasovagal"],"enrollment":143,"completionDate":"2023-08-31"},{"nctId":"NCT06237751","phase":"NA","title":"Preoperative Sildenafil Administration for Hepatectomy","status":"RECRUITING","sponsor":"First People's Hospital of Chenzhou","startDate":"2024-02-01","conditions":["Central Venous Pressure","Hepatectomy","Hemodynamics Instability","Sildenafil"],"enrollment":16,"completionDate":"2024-12-30"},{"nctId":"NCT06428669","phase":"PHASE4","title":"Effect of Nitropaste in Chest Masculinizing Surgery","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-08-15","conditions":["Gender Dysphoria"],"enrollment":256,"completionDate":"2025-11"},{"nctId":"NCT04284345","phase":"NA","title":"Saline-induced Distal to Aortic Coronary Pressure Ratio vs. Resting and Hyperemic Indices of Coronary Artery Stenosis Severity","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2020-01-31","conditions":["Coronary Stenosis"],"enrollment":90,"completionDate":"2024-01-01"},{"nctId":"NCT04318990","phase":"NA","title":"DIstal vs Proximal Radial Artery Access for Cath","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2020-03-06","conditions":["Coronary Angiography","Coronary Angioplasty"],"enrollment":300,"completionDate":"2022-12-31"},{"nctId":"NCT04573751","phase":"NA","title":"The EPIVER Randomized Controlled Trial","status":"COMPLETED","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2020-12-30","conditions":["ST Elevation Myocardial Infarction","Percutaneous Coronary Intervention","No-Reflow Phenomenon"],"enrollment":104,"completionDate":"2024-01-31"},{"nctId":"NCT05102734","phase":"","title":"Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-09-01","conditions":["Circulatory Shock","Cardiovascular Shock"],"enrollment":44,"completionDate":"2022-03-01"},{"nctId":"NCT02870985","phase":"NA","title":"BIOTRONIK Orsiro Pre-Marketing Registration","status":"COMPLETED","sponsor":"Biotronik (Beijing) Medical Device Ltd.","startDate":"2015-07-14","conditions":["Coronary Artery Disease"],"enrollment":440,"completionDate":"2021-12"},{"nctId":"NCT06289946","phase":"PHASE2","title":"Topical Nitro or Placebo Pre-Cath","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2024-03-01","conditions":["Coronary Artery Disease"],"enrollment":256,"completionDate":"2025-03-31"},{"nctId":"NCT04396223","phase":"PHASE1,PHASE2","title":"Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-02-12","conditions":["Gestational Trophoblastic Neoplasias (GTN)"],"enrollment":26,"completionDate":"2028-10-12"},{"nctId":"NCT06265415","phase":"NA","title":"Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2024-03-30","conditions":["Severe Preeclampsia"],"enrollment":60,"completionDate":"2025-03-30"},{"nctId":"NCT06259760","phase":"","title":"AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia","status":"RECRUITING","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2024-03-01","conditions":["Acute Kidney Injury (Nontraumatic)","Hypotension Drug-Induced"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT06210217","phase":"EARLY_PHASE1","title":"Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2024-02-01","conditions":["Laparoscopic Hepatectomy"],"enrollment":51,"completionDate":"2024-04-07"},{"nctId":"NCT01704274","phase":"PHASE2","title":"GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy","status":"COMPLETED","sponsor":"Dr. D. Robert Siemens","startDate":"2012-04","conditions":["Prostate Cancer"],"enrollment":43,"completionDate":"2019-12"},{"nctId":"NCT03251599","phase":"PHASE4","title":"The Effect of Nitroglycerin Infusion Rate on Cerebral Rewarming During Hypothermic Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"Recep Tayyip Erdogan University","startDate":"2017-08-16","conditions":["Coronary Artery Bypass","Cardiopulmonary Bypass"],"enrollment":78,"completionDate":"2017-11-22"},{"nctId":"NCT04775914","phase":"NA","title":"STEMI Treatment Optimization by Ischemic Postconditioning and IVUS Guidance","status":"RECRUITING","sponsor":"Thomas Engstrom","startDate":"2021-04-01","conditions":["ST Elevation Myocardial Infarction"],"enrollment":2500,"completionDate":"2031-02-01"},{"nctId":"NCT06172998","phase":"EARLY_PHASE1","title":"New Perspective on Exploring the Post-apneic BP Surge in Patients With OSA","status":"UNKNOWN","sponsor":"Xu J","startDate":"2022-04-01","conditions":["Obstructive Sleep Apnea"],"enrollment":350,"completionDate":"2024-06-01"},{"nctId":"NCT04564521","phase":"NA","title":"Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2020-09-28","conditions":["Retinoblastoma"],"enrollment":36,"completionDate":"2024-12-30"},{"nctId":"NCT05771961","phase":"NA","title":"Impact of Rotational Atherectomy on Coronary Microcirculation","status":"UNKNOWN","sponsor":"Lithuanian University of Health Sciences","startDate":"2023-05-01","conditions":["Stable Angina","Coronary Artery Disease"],"enrollment":300,"completionDate":"2025-05-01"},{"nctId":"NCT06107465","phase":"PHASE2,PHASE3","title":"High Versus Low Dose Nitroglycerin in Acute Pulmonary Edema","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2023-11-10","conditions":["Pulmonary Edema"],"enrollment":60,"completionDate":"2024-07"},{"nctId":"NCT04221594","phase":"","title":"Quantification of Myocardial Blood Flow Using Dynamic PET/CTA Fused Imagery","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-01","conditions":["Coronary Artery Disease"],"enrollment":68,"completionDate":"2023-06-30"},{"nctId":"NCT05561959","phase":"NA","title":"Efficacy of Phonophoresis With Topical Glyceryl Trinitrate in Treatment of Achilles Tendinopathy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-11-01","conditions":["Non Insertional Achilles Tendinopathy"],"enrollment":64,"completionDate":"2023-04-01"},{"nctId":"NCT04085094","phase":"","title":"Gender Differences in Renal Functioning and Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2017-05-30","conditions":["Chronic Renal Failure","Healthy Controls"],"enrollment":98,"completionDate":"2019-12-02"},{"nctId":"NCT05393557","phase":"NA","title":"Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2024-01-01","conditions":["STEMI","Large Thrombus Burden","No-Reflow Phenomenon"],"enrollment":626,"completionDate":"2026-11-30"},{"nctId":"NCT05907655","phase":"","title":"Study of the Glymphatic System in Migraine","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2023-04-30","conditions":["Migraine"],"enrollment":50,"completionDate":"2026-04-30"},{"nctId":"NCT04125992","phase":"NA","title":"Distal vs. Forearm Radial Artery Access","status":"COMPLETED","sponsor":"An-Najah National University","startDate":"2019-12-01","conditions":["Coronary Artery Disease","Angina, Unstable","Angina, Stable","Non STEMI","Non ST Segment Elevation Myocardial Infarction","Acute Coronary Syndrome","Atheroscleroses, Coronary","Atherosclerotic Heart Disease With Ischemic Chest Pain","Chest Pain","Myocardial Infarction","Myocardial Ischemia","ST-segment Elevation Myocardial Infarction (STEMI)"],"enrollment":212,"completionDate":"2020-12-21"},{"nctId":"NCT05814991","phase":"","title":"A Cohort Prospective Study of Predictors Influencing the Quality of Visualization of the Operating Field During Orthognathic Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","startDate":"2023-05-29","conditions":["Malocclusion","Maxillofacial Injuries","Orthodontics","Hemorrhage"],"enrollment":100,"completionDate":"2026-06-15"},{"nctId":"NCT04664140","phase":"NA","title":"QFR-based Virtual PCI Versus Angio-guided PCI","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2021-02-20","conditions":["Percutaneous Coronary Intervention","Coronary Physiology"],"enrollment":300,"completionDate":"2023-05-09"},{"nctId":"NCT05837403","phase":"PHASE3","title":"The Use of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure","status":"COMPLETED","sponsor":"Al-Kindy College of Medicine","startDate":"2020-10-01","conditions":["Fissure in Ano"],"enrollment":460,"completionDate":"2022-09-30"},{"nctId":"NCT05590520","phase":"NA","title":"Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure","status":"UNKNOWN","sponsor":"Pak Emirates Military Hospital","startDate":"2022-11-01","conditions":["Fissure in Ano"],"enrollment":90,"completionDate":"2024-12"},{"nctId":"NCT04944615","phase":"NA","title":"To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.","status":"RECRUITING","sponsor":"CCRF Inc., Beijing, China","startDate":"2022-10-21","conditions":["Chronic Total Occlusion of Coronary Artery"],"enrollment":1448,"completionDate":"2031-10"},{"nctId":"NCT05405192","phase":"PHASE2","title":"Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2023-03-01","conditions":["Gestational Trophoblastic Neoplasia"],"enrollment":0,"completionDate":"2028-12-01"},{"nctId":"NCT03305848","phase":"PHASE4","title":"Esophageal Food Impaction","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2017-08-25","conditions":["Esophageal Food Bolus Obstruction"],"enrollment":20,"completionDate":"2019-04-04"},{"nctId":"NCT05718310","phase":"NA","title":"Habituation of the Nociceptive Blink Reflex in Experimentally Induced Migraine Attack","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2022-11-01","conditions":["Migraine","Migraine Disorders","Pain"],"enrollment":22,"completionDate":"2024-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Sublingual","formulation":"Aerosol, Capsule, Film, Injection","formulations":[{"form":"AEROSOL, METERED","route":"SUBLINGUAL","productName":"NitroMist"},{"form":"AEROSOL, METERED","route":"SUBLINGUAL","productName":"Nitroglycerin"},{"form":"CAPSULE","route":"ORAL","productName":"Nitro-Time"},{"form":"CAPSULE","route":"ORAL","productName":"Nitroglycerin"},{"form":"CAPSULE","route":"ORAL","productName":"Nitro-Time"},{"form":"CAPSULE","route":"ORAL","productName":"Nitroglycerin Slocaps"},{"form":"CAPSULE","route":"ORAL","productName":"NITRO-TIME"},{"form":"CAPSULE","route":"ORAL","productName":"NitroglycerinER"},{"form":"FILM, EXTENDED RELEASE","route":"TRANSDERMAL","productName":"Nitroglycerin"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"NITROGLYCERIN IN  DEXTROSE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Nitroglycerin In Dextrose"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"NITROGLYCERIN"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Nitroglycerin"},{"form":"LIQUID","route":"ORAL","productName":"CardioforceI"},{"form":"LIQUID","route":"ORAL","productName":"HBP"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000145909","MMSL":"2324","NDDF":"000683","UNII":"G59M7S0WS3","VUID":"4017525","CHEBI":"CHEBI:28787","VANDF":"4017525","RXNORM":"4917","UMLSCUI":"C0017887","chemblId":"CHEMBL730","ChEMBL_ID":"CHEMBL730","KEGG_DRUG":"D00515","DRUGBANK_ID":"DB00727","PDB_CHEM_ID":" TNG","PUBCHEM_CID":"4510","SNOMEDCT_US":"387404004","IUPHAR_LIGAND_ID":"7053","MESH_DESCRIPTOR_UI":"D005996"},"formularyStatus":[],"originalProduct":{"form":"OINTMENT","route":"TOPICAL","company":"Savage Laboratories a division of Fougera Pharmaceuticals Inc.","brandName":"NITRO-BID","isOriginal":true,"marketingStatus":"ANDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1981-","companyName":"Fougera","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.5 hours","clearance":"194.3 mL/min/kg","bioavailability":"1%","fractionUnbound":"0.4%"},"publicationCount":2647,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C01DA02","allCodes":["C01DA02","C01DA52","C05AE01"]},"biosimilarFilings":[],"originalDeveloper":"Fougera","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Fougera","companyId":"fougera","modality":"Small molecule","firstApprovalDate":"1981","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1981-05-28T00:00:00.000Z","mah":"FOUGERA","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1981-05-28T00:00:00.000Z","mah":"FOUGERA","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1981-05-28T00:00:00.000Z","mah":"FOUGERA","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1981-05-28T00:00:00.000Z","mah":"FOUGERA","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1981-05-28T00:00:00.000Z","mah":"FOUGERA","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1981-05-28T00:00:00.000Z","mah":"FOUGERA","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7872049","territory":"US","patent_type":null,"expiry_date":"2029-03-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9101592","territory":"US","patent_type":null,"expiry_date":"2032-03-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":27,"withResults":4},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:44:51.740958+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}